US 11,946,936 B2
Beta-catenin inhibitors in cancer immunotherapy
Thomas Gajewski, Chicago, IL (US); and Stefani Spranger, Chicago, IL (US)
Assigned to The University of Chicago, Chicago, IL (US)
Filed by The University of Chicago, Chicago, IL (US)
Filed on Jul. 20, 2020, as Appl. No. 16/933,614.
Application 16/933,614 is a continuation of application No. 15/555,099, granted, now 10,753,938, previously published as PCT/US2016/020944, filed on Mar. 4, 2016.
Claims priority of provisional application 62/128,285, filed on Mar. 4, 2015.
Prior Publication US 2021/0148917 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/574 (2006.01); A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); C12N 15/113 (2010.01)
CPC G01N 33/57496 (2013.01) [A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5017 (2013.01); G01N 33/57484 (2013.01); G01N 33/57492 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4706 (2013.01); G01N 2333/70517 (2013.01)] 21 Claims
 
1. A method for the treatment of solid tumor cancer in a subject that has one or more tumors that exclude T-cell infiltration, the method comprising (a) testing tumor cells or tissue from a subject for one or more of: (i) exclusion of T cell infiltration, (ii) transcriptional repression of chemokine CCL4, (iii) defective recruitment of CD103+dendritic cells; and (b) co-administrating (i) a β-catenin inhibitor and/or a Wnt/β-catenin pathway inhibitor and (ii) dendritic-cell therapy or T-cell therapy to the subject.